Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Winner of 2010 BioNetwork East, The 1st Annual Perfect Pitch, Biotech Investment Challenge Announced

Miami, FL. March 22, 2010 – Diffusion Pharmaceuticals LLC is the winner of the 1st Annual Perfect Pitch- Biotech Investment Challenge. The winner was announced March 16, 2010 at a special awards ceremony attended by over 150 delegates and guests at the Eden Roc Resort & Spa in Miami, FL.
 
Diffusion Pharmaceuticals LLC was selected by a panel of judges who reviewed and evaluated four company presentations given on March 16, 2010 at the BioNetwork East Conference. 
 
“Given the economic climate, it is becoming increasingly difficult to shore up funding for R&D programs in the pharmaceutical sector. Having a compelling company story and innovative drug development program are crucial to ensuring successful partnerships or investments.  The BioNetwork East Conference highlighted four of the most promising drug development programs currently underway,” said Brie McInerney, Conference Director, BioNetwork.  
 
Here are the finalists and winner of the 1st Annual Perfect Pitch- Biotech Investment Challenge:
 
Winner: Diffusion Pharmaceuticals LLC
Presenter: David G. Kalergis, JD/MBA, Chief Executive Officer & Co-Founder
 
Diffusion Pharmaceuticals is a clinical-stage drug-development company commercializing first-in-class drug candidates. Our lead product candidate, trans sodium crocetinate (NASDAQ:TSC), is a synthetic small-molecule that uses a novel method of action to enhance oxygen diffusion to oxygen-deprived (hypoxic) tissue. Diffusion Pharmaceuticals believes that TSC has the potential to treat millions of patients annually for conditions in which hypoxia is present, including cardiovascular and respiratory diseases, stroke, cancer and other serious conditions with unmet medical needs.
 
Finalist: Catalyst Pharmaceutical Partners
Presenter: Patrick McEnany, Co-Founder, Chairman, President & Chief Executive Officer
 
Catalyst is a specialty pharmaceutical company of Coral Gables, Florida, that acquires or in-licenses, develops and commercializes prescription drugs for the treatment of drug addiction. Catalyst is developing vigabatrin (designated CPP-109 by Catalyst) for the treatment of addiction to cocaine, methamphetamine and other addictive substances.
 
Finalist: Oragenics
Presenter: David B. Hirsch, President & Chief Executive Officer
 
Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies and a primary focus on commercialization. In addition to marketed products based on the ProBiora3 technology, the Company also has a number of products in discovery, preclinical and clinical development, with a concentration in the main therapeutic area of infectious diseases, in diagnostics, and in oral health.  
 
Finalist: Symphogen
Presenter: Adriann Sax, B.Sc., MBA, Chief Business Officer
 
Symphogen is developing superior antibody therapeutics to help people with serious diseases. With its proprietary SymplexTM discovery and SympressTM manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a pipeline of internal and partnered products across multiple indications including cancer and infectious disease.
 
BioNetwork East has enlisted a panel of judges from large pharmaceutical companies and investment firms. These panelists are responsible for evaluating drug development programs worldwide and shared their insights with the finalists and attendees during the Biotech Investment Challenge. The judges included:
Robert Bagdorf, VP, Worldwide Business Development, Pfizer Mark Benedyk, Head, The Pfizer Incubator LLC David H. Donabedian, VP, Strategic Alliances, US CEEDD, GlaxoSmithKline Frank Stokes, Managing Director, R.W. Baird
 
For further information on this year’s investment challenge or information on future programs, contact:
Brie McInerney
BioNetwork Conference Director
646-200-7527
Brie.McInerney@wbresearch.com
 
About BioNetwork
The BioNetwork Conferences are produced by Worldwide Business Research. Both BioNetwork East and West events provide an essential meeting place for business development executives within the pharmaceutical industry. According to Brie McInerney, Conference Director of Bionetwork, The BioNetwork Events have solidified their place as the premier partnering conferences for pharmaceutical executives looking to engage partners and execute deals. For more information about BioNetwork, visit www.bionetworkus.com. Register for BioNetwork with booking code 10386XA364 to get a 25% discount. Register online at www.bionetworkus.com or call 646-200-7530.